Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG005 combined with gecacitinib hydrochloride in advanced cervical cancer
CTR20252686Phase 2Active
- Sponsor
- Zelgen
- Start
- Sep 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nilvanstomig and jaktinib in Cervical Cancer (CC) (3 arms), sponsored by Zelgen. Primary endpoints: Adverse events, Recommended phase II dosing regimen and 1 more. Started Sep 2025; status: active.
02
Drugs
nilvanstomigjaktinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20252686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252686.